In our study, providers did not feel comfortable prescribing risk-reducing chemoprevention medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who were at high risk for developing breast cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.